医学
无容量
多西紫杉醇
肿瘤科
内科学
肺癌
中期分析
随机对照试验
危险系数
化疗
临床试验
癌症
不利影响
免疫疗法
置信区间
作者
Dickran Gano Kazandjian,Sean Khozin,Gideon Michael Blumenthal,Lijun Zhang,Shenghui W. Tang,Meredith Libeg,Paul Gustav Kluetz,Rajeshwari Sridhara,Patricia Keegan,Richard Pazdur
出处
期刊:JAMA Oncology
[American Medical Association]
日期:2015-10-15
卷期号:2 (1): 118-118
被引量:59
标识
DOI:10.1001/jamaoncol.2015.3934
摘要
IMPORTANCE: Metastatic squamous non-small-cell lung cancer (SQ NSCLC) is a serious and life-threatening malignant condition with unmet medical need. In late December 2014, the US Food and Drug Administration (FDA) obtained the data monitoring committee report of a planned interim analysis of a trial in second-line SQ NSCLC (CM017) that demonstrated an overall survival benefit for patients treated with nivolumab compared with docetaxel. OBSERVATIONS: In that trial, 272 patients with metastatic SQ NSCLC patients had been randomized to receive nivolumab (n = 135) or docetaxel (n = 137). Median overall survival was 9.2 months for patients randomized to nivolumab and 6.0 months for those randomized to docetaxel (hazard ratio, 0.59; 95% CI, 0.44-0.79; P < .001). The safety of nivolumab was evaluated in a single-arm trial of 117 patients in previously treated metastatic SQ NSCLC and was consistent with the safety profile in melanoma, with rare but serious immune-mediated adverse events managed with corticosteroids and dose interruption. CONCLUSIONS AND RELEVANCE: The FDA granted nivolumab traditional approval on March 4, 2015, for treatment of metastatic SQ NSCLC with progression during or after platinum-based chemotherapy. The approval provides an important treatment option for these patients, affecting routine care and clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI